FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1549955270> ?p ?o ?g. }

• W1549955270 endingPage "398" @default.
• W1549955270 startingPage "391" @default.
• W1549955270 abstract "Aims/Introduction: To compare first-line, single-agent glimepiride and pioglitazone in Japanese patients with type 2 diabetes uncontrolled by diet and exercise with respect to glycemic control, safety and metabolic changes. Patients with previously untreated type 2 diabetes were enrolled in a multicenter, randomized, non-blind, parallel-group trial of glimepiride (0.5-6 mg/day) or pioglitazone (15-45 mg/day) for 6 months. A total of 191 patients aged 30-75 years were randomized. Similar percentages of patients attained the primary end-point, with glycated hemoglobin < 6.9% at month 6 with glimepiride and pioglitazone, respectively (61.2 vs 56.8%, P = 0.64). At month 6, the following significant (P < 0.05) intragroup changes in mean plasma lipid concentrations were noted as compared with baseline: total cholesterol decreased from 203.5 to 195.5 mg/dL and low-density lipoprotein (LDL)-cholesterol decreased from 124.5 to 116.3 mg/dL in the glimepiride group, whereas high-density lipoprotein (HDL)-cholesterol increased from 51.6 to 56.0 mg/dL and triglycerides decreased from 167.6 to 143.6 mg/dL in the pioglitazone group. The only symptomatic adverse events were mild-to-moderate in four patients receiving pioglitazone, and constipation in one patient receiving glimepiride. Similar numbers of patients experienced asymptomatic hypoglycemia (<60 mg/dL) in the glimepiride and pioglitazone groups (n = 7 and 5, respectively). There was no statistically significant difference between glimepiride and pioglitazone with respect to glycemic control, and both agents were well tolerated. Glimepiride significantly lowered total cholesterol and LDL-cholesterol, whereas pioglitazone increased HDL-cholesterol. This trial was registered with University Hospital Medical Information Network (UMIN), Japan, UMIN000004582. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2011.00115.x, 2011)." @default.
• W1549955270 created "2016-06-24" @default.
• W1549955270 creator A5001368676 @default.
• W1549955270 creator A5040178487 @default.
• W1549955270 creator A5040548657 @default.
• W1549955270 creator A5044415438 @default.
• W1549955270 creator A5046224700 @default.
• W1549955270 creator A5047045330 @default.
• W1549955270 creator A5052412166 @default.
• W1549955270 creator A5057363086 @default.
• W1549955270 creator A5077189198 @default.
• W1549955270 creator A5078251739 @default.
• W1549955270 creator A5088387334 @default.
• W1549955270 date "2011-04-03" @default.
• W1549955270 modified "2023-10-16" @default.
• W1549955270 title "Randomized controlled trial of single-agent glimepiride and pioglitazone in Japanese patients with type 2 diabetes: A comparative study" @default.
• W1549955270 cites W1968973887 @default.
• W1549955270 cites W1982194579 @default.
• W1549955270 cites W1986364721 @default.
• W1549955270 cites W1990724339 @default.
• W1549955270 cites W1997416444 @default.
• W1549955270 cites W2003112894 @default.
• W1549955270 cites W2019473338 @default.
• W1549955270 cites W2064617441 @default.
• W1549955270 cites W2095727328 @default.
• W1549955270 cites W2097395605 @default.
• W1549955270 cites W2099816538 @default.
• W1549955270 cites W2104785880 @default.
• W1549955270 cites W2116836307 @default.
• W1549955270 cites W2127125241 @default.
• W1549955270 cites W2150556712 @default.
• W1549955270 cites W2154580171 @default.
• W1549955270 cites W2159969745 @default.
• W1549955270 cites W2171294019 @default.
• W1549955270 cites W92458862 @default.
• W1549955270 doi "https://doi.org/10.1111/j.2040-1124.2011.00115.x" @default.
• W1549955270 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4019308" @default.
• W1549955270 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24843519" @default.
• W1549955270 hasPublicationYear "2011" @default.
• W1549955270 type Work @default.
• W1549955270 sameAs 1549955270 @default.
• W1549955270 citedByCount "5" @default.
• W1549955270 countsByYear W15499552702012 @default.
• W1549955270 countsByYear W15499552702013 @default.
• W1549955270 countsByYear W15499552702015 @default.
• W1549955270 countsByYear W15499552702017 @default.
• W1549955270 crossrefType "journal-article" @default.
• W1549955270 hasAuthorship W1549955270A5001368676 @default.
• W1549955270 hasAuthorship W1549955270A5040178487 @default.
• W1549955270 hasAuthorship W1549955270A5040548657 @default.
• W1549955270 hasAuthorship W1549955270A5044415438 @default.
• W1549955270 hasAuthorship W1549955270A5046224700 @default.
• W1549955270 hasAuthorship W1549955270A5047045330 @default.
• W1549955270 hasAuthorship W1549955270A5052412166 @default.
• W1549955270 hasAuthorship W1549955270A5057363086 @default.
• W1549955270 hasAuthorship W1549955270A5077189198 @default.
• W1549955270 hasAuthorship W1549955270A5078251739 @default.
• W1549955270 hasAuthorship W1549955270A5088387334 @default.
• W1549955270 hasBestOaLocation W15499552702 @default.
• W1549955270 hasConcept C126322002 @default.
• W1549955270 hasConcept C134018914 @default.
• W1549955270 hasConcept C168563851 @default.
• W1549955270 hasConcept C2776307423 @default.
• W1549955270 hasConcept C2777180221 @default.
• W1549955270 hasConcept C2777538456 @default.
• W1549955270 hasConcept C2778384471 @default.
• W1549955270 hasConcept C2780473172 @default.
• W1549955270 hasConcept C2780668416 @default.
• W1549955270 hasConcept C555293320 @default.
• W1549955270 hasConcept C71924100 @default.
• W1549955270 hasConcept C90924648 @default.
• W1549955270 hasConceptScore W1549955270C126322002 @default.
• W1549955270 hasConceptScore W1549955270C134018914 @default.
• W1549955270 hasConceptScore W1549955270C168563851 @default.
• W1549955270 hasConceptScore W1549955270C2776307423 @default.
• W1549955270 hasConceptScore W1549955270C2777180221 @default.
• W1549955270 hasConceptScore W1549955270C2777538456 @default.
• W1549955270 hasConceptScore W1549955270C2778384471 @default.
• W1549955270 hasConceptScore W1549955270C2780473172 @default.
• W1549955270 hasConceptScore W1549955270C2780668416 @default.
• W1549955270 hasConceptScore W1549955270C555293320 @default.
• W1549955270 hasConceptScore W1549955270C71924100 @default.
• W1549955270 hasConceptScore W1549955270C90924648 @default.
• W1549955270 hasIssue "5" @default.
• W1549955270 hasLocation W15499552701 @default.
• W1549955270 hasLocation W15499552702 @default.
• W1549955270 hasLocation W15499552703 @default.
• W1549955270 hasLocation W15499552704 @default.
• W1549955270 hasOpenAccess W1549955270 @default.
• W1549955270 hasPrimaryLocation W15499552701 @default.
• W1549955270 hasRelatedWork W1549955270 @default.
• W1549955270 hasRelatedWork W1868211825 @default.
• W1549955270 hasRelatedWork W2033522292 @default.
• W1549955270 hasRelatedWork W2081043891 @default.
• W1549955270 hasRelatedWork W2141358021 @default.
• W1549955270 hasRelatedWork W2329018285 @default.
• W1549955270 hasRelatedWork W2341560996 @default.
• W1549955270 hasRelatedWork W3016463962 @default.

• next